Non Invasive Diagnostics - A Painless, Non-Invasive, Radiation-Free Device to Detect - iCrowdNewswire

RSS Newsfeeds

See all RSS Newsfeeds

Jul 8, 2015 7:04 AM ET

Non Invasive Diagnostics – A Painless, Non-Invasive, Radiation-Free Device to Detect

iCrowdNewswire - Jul 8, 2015


Non Invasive Diagnostics

A Painless, Non-Invasive, Radiation-Free Device to Detect


Widespread efforts to raise awareness have succeeded, with the vast majority of women in developed nations undergoing routine breast cancer screenings, involving palpation (physical examination) and/or mammography. Unfortunately, both screening processes produce highly inaccurate results that take a personal and financial toll. Upwards of 20% of breast lumps found through palpation are not studied further, and turn out to be malignant and possibly deadly.

The Non Invasive Diagnostic System (or NIDS) reduces the risk of misdiagnosis and increases the chance of early detection of breast cancer. Our innovative device detect 95% of all cancer, a 30% improvement over traditional mammography.


NIDS is a non-invasive, painless, and radiation-free diagnostic device. It can be operated by an easily-trained technician in less than 15 minutes in any standard medical office setting. This ease of use creates a substantial cost-savings for both doctors and patients when compared to current diagnostic methods.

NIDS also provides physiological information that helps physicians characterize ambiguous breast findings after palpation or mammography. Prior to NIDS, these findings typically required a painful and invasive breast biopsy in order to determine malignancy.

NIDS can determine whether or not ambiguous lesions are potentially malignant without mammography or biopsy. Our technology can eliminate 55% of unnecessary biopsies in women 55 and younger.


NIDS determines the biological activity of breast lesions (areas of concern that can potentially be cancerous) by utilizing a non-invasive measurement of differentials in breast tissue through sensors that are attached to a patient.

From there, a comparison is made between resting polarized cells (healthy) and rapidly dividing, depolarized cells (potentially cancerous). A NIDS Diagnostic Score compares the activity of an unaffected portion of the breast with one that may contain cancerous cells.


Detects 95%+ of cancer (a 30% improvement over mammography)

Determines whether or not ambiguous lesions are potentially malignant without mammography or biopsy

Non invasive, radiation-free and painless

Eliminates 50% of equivocal results which lead to unnecessary biopsies (a 40% improvement over mammography)

In-office procedure that only takes 15 minutes and produces objective results




Richard Blumberg Esq., – Managing Member, Chairman



Rick holds a B.S. in Electrical Engineering and Computer Science from the University of Illinois and a J.D. Stanford University. He currently is a principal at Webster Mrak & Blumberg, medical-legal and class action labor litigation firm; judgments and verdicts exceeding $150 million. He is also a venture capital entrepreneur in high-tech and life sciences companies. He has served as CEO of Energy Logics (EL), a wind power development company with projects in Alberta and Montana that was acquired. He is a major shareholder in Insync Analytics as a co-development strategist of stock and commodity analytical trading tool presently used in-house to trade stocks and commodities. He is an instrumental investor in three public companies: 1) two Bio Medical companies where he served as a strategic advisor to the management team and the board of directors, and 2) a company with multiple patents for a conductive plastic that provides lightweight electromagnetic shielding for mobile power supplies, such as batteries for cars and electronic products, and consumer electronics, with multiple contracts and joint development agreements with global manufacturers of such products. He also serves on the board of directors of the latter company.


Michael Antonoplos – Managing Member, COO



Michael holds a B.S. in psychology and political science from the University of Pittsburgh. He is a principal of a firm he started in 2000 which provides debt and equity for a variety of investment opportunities. As a partner in a privately held real estate investment fund, Mr. Antonoplos was instrumental in raising and placing from the private sector over $500 million. Mr. Antonoplos has served as an officer and board member for three U.S. public companies. In his capacity as CEO and board member for a public Bio-Medical company he directed the retirement of over $3 million of note-holder debt and the subsequent investment by the lead note-holder of capital into the company of over $500K. In addition, he framed and implemented the transition of the company to the OTCBB followed by a reverse split resulting in an increase in shareholder value of over 25%. Mr. Antonoplos served a two-year term on the board of directors as audit committee chairman for a U.S. public company based in China. He helped negotiate the sale of two operating groups and the acquisition of three companies resulting in an increase in shareholder value of 15%. Mr. Antonoplos served as Receiver for a company under an appointment from a U.S. Federal District Court. In this capacity he was responsible for overseeing the operation of the enterprise, managing its bank accounts, and obtaining funds to satisfy a judgment against the company while maintaining the viability of the company.


Robert Albus – Member, President



In addition to his M&A experience, Bob provides a financial, corporate marketing and general management background to Goodrich Capital client companies. He has worked with Private Equity firms as a senior operating executive and Board advisor for the past five years. Prior to this he was President of Premier Inc, a consumer products company he founded and sold to Advanced Polymer Systems where he became President of the Toiletry Division. Bob began his career with Johnson & Johnson, moved to CBS as Vice President of Business Development of WB Saunders for the Publishing Group, and subsequently became Marketing Director of Combe Inc. and General Manager of Combe Canada. Bob earned a BA degree from Lafayette College and MBA from Lehigh University.


Mark S. Pearlstein, Esq. – Member, General Counsel



Mark is an accomplished commercial litigator and corporate attorney with 30 years of experience counseling and representing corporate and governmental organizations at the highest levels. He has widespread experience with businesses entities of all sizes and stages of development, and is known for judicious counsel in strategic decisions and for perseverance and excellence in executing adopted legal strategies in transactions and litigation. He has held very senior responsibilities in assignments for U.S. Navy Judge Advocate General including, inter alia. He served as counsel to Secretary of the Navy’s Gratuity Board investigating various companies, lead counsel to Navy/Marine Corps in Federal Court litigation in defense of urinalysis program; and successful defense with resultant saving to client of approximately one-half billion dollars. His educational background includes LL.M. (International Law) Georgetown University Law Center, an M.B.A. California State University (Dominguez Hills), J.D. from Temple University School of Law, and a B.A. Temple University Licenses: State: Pennsylvania; New Jersey; New York. Federal: U.S. Court of Appeals for Third and Federal Circuits; U.S. District Court for E.D.Pa.; D.N.J.; S.D.N.Y.; U.S. Court of Federal Claims; U.S. Court of Appeals for the Armed Forces.


Charles Rufai, CPA – Member, CFO



Charles has over 25 years experience in accounting and finance. He has held positions as Financial Reporting Manager, Corporate Treasurer, Corporate Controller, and Corporate Chief Financial officer. His experience has spanned the fields of Insurance, Banking, Real Estate, Asset Management and Certified Public Accounting; and has been with both publicly and privately held companies. He also has extensive internal and external audit experience. Charles has a BS degree in Accounting and he is a Certified Public Accountant in New York and New Jersey.


Ronald Hart, PhD. – Member, Regulatory Approvals



Dr. Hart received his physiology and biophysics from the University of Illinois in 1971. He assumed the post of assistant professor at The Ohio State University in 1971, becoming a full regents professor in 1978. In 1980, he was named director of the National Center for Toxicological Research (NCTR) and in 1992, became the first person in the eighty year history of the U.S .Food and Drug Administration to be named “distinguished scientist in residence”. Dr. Hart is an internationally recognized scientist and scholar, serving on the editorial boards of more than a dozen professional journals, author or co-author of over 450 scientific publications, and editor of six scientific volumes. Dr. Hart is credited with developing the first direct proof that DNA damage is causal in sunlight-induced cancer. He is internationally recognized for his pioneering work in aging, and his studies on nutrition and health. As a result of his contributions to science, Dr. Hart has received over two dozen national and international awards and recognitions including the Karl-August-Forester-President of the German Academy of Sciences and Literature, been appointed to the post of distinguished professor at a number of universities including: Cairo University, Seoul National University and Guangzhou University and has been elected a fellow of the Hudson Institute, Gerontological Society,American College of Toxicology (where he served as president in 1981), American Association for the Advancement of Science, and the Association of Clinical Scientists and has been featured in at least one popularized book.


The challenge for any diagnostic test is that it is very difficult to simultaneously achieve both high sensitivity (a measure of a test’s ability to identify the presence of disease) and high specificity (a test’s ability to identify the absence of disease). Usually a threshold is defined that represents the best clinical trade-off between sensitivity and specificity. If a test is sensitive enough (>90%), negative results can be used to safely rule out the presence of disease. Positive results associated with a high specificity test are used to rule in the presence of disease.

Neither of the major breast screening processes — palpation or mammography – is a rule-out procedure. Both require additional and often invasive testing. Typically, mammography’s sensitivity rate is 60-70% in younger women, and can exceed 80% for older women. With these sensitivity rates, mammography misses many malignant lumps, especially in younger women. At the same time, its 14% specificity rate leads to upwards of 86% unnecessary biopsies.

Seven worldwide clinical studies involving over 1,600 women have proven that NIDS was able to detect between 90% and 100% of those malignancies, a 30% improvement over mammography. These findings have been documented in several peer-reviewed journals.

We have significantly reduced the need for women being referred for additional costly tests (including biopsies) by more than half, representing a 40% improvement over mammography. The NIDS greatly decreases the occurrence of needless, painful and invasive biopsies, granting women of all ages unprecedented peace of mind.

Contact Information:

Richard Blumberg Esq
Michael Antonoplos
Robert Albus

View Related News >